American Pharmaceutical Partners recently presented Phase II data, and anticipation prior to FDA meeting data of January 8th has caused the stock to run up recently. Shorts feel their pivotal trial was underpowered, among other things.
EYET has run up. I always felt it would get approval, and that would be the time to short it. I didn't get in on the anticipatory run from $43 to $46. Ian has pointed out the risks relative to QLTI. But there is probably some risk in the label.
OSIP's huge gap up on Iressa's failure to demonstrate survival benefit.
NBIX up as if the great label for Lunesta meant the FDA was going to be nice to them, too, and they've got Pfizer behind them, as well as 12 month studies, too, blah blah. Nothing has changed for NBIX, it was SEPR that had some uncertainty in it.
I've ordered these in terms of insticintive feel for risk/reward, with the lowest (most compelling short) first.
Anybody want to flesh out rationale, or add some fresh candidates as valuation make there seasonal way towrds less reasonable?
Cheers, Tuck |
